Analysts Conflicted on These Healthcare Names: NuVasive (NASDAQ: NUVA) and NanoString Tech (NASDAQ: NSTG)

By Jason Carr

Analysts have been eager to weigh in on the Healthcare sector with new ratings on NuVasive (NASDAQ: NUVA) and NanoString Tech (NASDAQ: NSTG).

NuVasive (NASDAQ: NUVA)

In a report released today, Jeff Johnson from Robert W. Baird maintained a Hold rating on NuVasive (NASDAQ: NUVA), with a price target of $60. The company’s shares opened today at $50.05, close to its 52-week low of $49.25.

According to TipRanks.com, Johnson is a 3-star analyst with an average return of 3.3% and a 60.0% success rate. Johnson covers the Healthcare sector, focusing on stocks such as Varian Medical Systems, Zimmer Biomet Holdings, and Wright Medical Group.

NuVasive has an analyst consensus of Strong Buy, with a price target consensus of $79.18.

NanoString Tech (NASDAQ: NSTG)

Robert W. Baird analyst Catherine Schulte maintained a Buy rating on NanoString Tech (NASDAQ: NSTG) today and set a price target of $19. The company’s shares opened today at $12.26.

According to TipRanks.com, Schulte is a 5-star analyst with an average return of 20.8% and a 82.4% success rate. Schulte covers the Healthcare sector, focusing on stocks such as Meridian Bioscience Inc, Bio-Techne Corporation, and Oxford Immunotec.

Currently, the analyst consensus on NanoString Tech is Moderate Buy and the average price target is $18, representing a 46.8% upside.

In a report issued on September 27, Cowen & Co. also reiterated a Buy rating on the stock with a $20 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.